

## **CURRICULUM VITAE**

### **PERSONAL INFORMATION AND CONTACTS**

---

First Name: Marzia

Surname: Varettoni

Date of Birth: 13<sup>th</sup> January 1972

Place of Birth: Pieve di Cadore, Belluno, Italy

Work address:

Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo

Viale Golgi 19, Zip code 27100, Pavia, Italy

Phone: +39-0382-503082

Fax: +39-0382-502250

E-mail: [m.varettoni@smatteo.pv.it](mailto:m.varettoni@smatteo.pv.it)

### **LANGUAGES**

---

Italian: native language

English: good ability in speaking, writing and understanding language (Level B1)

### **EDUCATION AND TRAINING**

---

Medical Degree in 1997 at the University of Pavia Medical School, Pavia, Italy.

Board Certification in Hematology in 2001 at the University of Pavia Medical School, Pavia, Italy

### **CURRENT POSITION**

---

2008-ongoing: Attending Physician at the Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

### **EXPERIENCE IN CLINICAL TRIALS**

---

Partecipation as principal investigator or co-investigator in several phase II and III clinical trials in transplantation, multiple myeloma, Waldenström's Macroglobulinemia, non-Hodgkin's lymphomas, chronic lymphocytic leukemia, hairy cell leukemia (2003-ongoing).

### **RESEARCH AREAS**

---

Autologous and allogeneic stem cell transplantation (1997-2001), multiple myeloma (2003-2010), Waldenström's Macroglobulinemia (2003-ongoing), monoclonal gammopathies of undetermined

significance (2003-ongoing), indolent non-Hodgkin's lymphomas (2011-ongoing), T cell lymphomas (2016-ongoing), chronic lymphocytic leukemia (2018-ongoing)

## MEMBERSHIP

---

Member of the Cooperative Group Fondazione Italiana Linfomi (FIL)

Member of the FIL commission of T cell lymphomas (2018-2019)

Member of the FIL commission of indolent lymphomas (2020-ongoing)

## SCIENTIFIC ACTIVITY

---

Author of 82 peer-reviewed papers; approximately 20 oral communications in national and international congresses; reviewer for Annals Oncology, Leukemia, British Journal of Haematology.

## AWARDS/GRANTS

---

- Recipient of Plenary Award at IX IWWM (Amsterdam 2016)
- Recipient of IWMM grant (2017)
- Recipient of "Ricerca corrente 2018-2020"

## LIST OF PUBLICATIONS

1. Basset M, Defrancesco I, Milani P, Nuvolone M, Rattotti S, Foli A, Mangiacavalli S, **Varettoni M**, Benvenuti P, Cartia CS, Paulli M, Merlini G, Arcaini L, Palladini G. Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. *Blood* 2020; 135:293-296.
2. **Varettoni M**, Boveri E, Zibellini S, Tedeschi A, Candido C, Ferretti VV, Rizzo E, Doni E, Merli M, Farina L, Goldaniga M, Galli A, Rattotti S, Frustaci AM, Deodato M, Bandiera L, Isimbaldi G, Uccella S, Cabras AD, Gianelli U, Baldini L, Paulli M, Arcaini L. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. *Am J Hematol.* 2019; 94:1193-1199.
3. Luminari S, Merli M, Rattotti S, Tarantino V, Marcheselli L, Cavallo F, **Varettoni M**, Bianchi B, Merli F, Tedeschi A, Cabras G, Re F, Visco C, Torresan Delamain M, Cencini E, Spina M, Ferrero S, Ferrari A, Deodato M, Mannina D, Annibali O, Rago A, Orsucci L, Defrancesco I, Frigeni M, Cesaretti M, Arcaini L. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. *Blood* 2019; 134:798-801.
4. **Varettoni M**, Zibellini S, Boveri E, Klersy C, Candido C, Rattotti S, Ferretti VV, Defrancesco I, Mangiacavalli S, Nizzoli ME, Flosspergher E, Zerbi C, Bergamini F, Benvenuti P, Brociner M, Merati G, Paulli M, Arcaini L. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. *Br J Haematol* 2019; 187:441-446.
5. Kastiris E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsenis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, **Varettoni M**, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA. A revised international prognostic score system for Waldenström's macroglobulinemia. *Leukemia* 2019; 33:2654-2661.
6. Rattotti S, Ferretti VV, Rusconi C, Rossi A, Fogazzi S, Baldini L, Pioltelli P, Balzarotti M, Farina L, Ferreri AJM, Laszlo D, Speziale V, **Varettoni M**, Sciarra R, Morello L, Tedeschi A, Frigeni M,

- Defrancesco I, Zerbi C, Flosspergher E, Nizzoli ME, Morra E, Arcaini L; "Rete Ematologica Lombarda" (REL - Hematology Clinical Network of Lombardy - Lymphoma Workgroup). Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. *Hematol Oncol* 2019;37:160-167.
7. Castillo JJ, Itchaki G, Paludo J, **Varettoni M**, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolosky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. *Blood* 2019; 133:299-305.
  8. Tedeschi A, Conticello C, Rizzi R, Benevolo G, Laurenti L, Petrucci MT, Zaja F, **Varettoni M**. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. *Hematol Oncol*. *Hematol Oncol*. 2019; 37:117-128.
  9. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. *N Engl J Med*. 2018;378:2399-2410.
  10. Guerrero ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, **Varettoni M**, Cazzola M, Treon SP, Hunter ZR. MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. *Haematologica* 2018;103:e408-e411.
  11. **Varettoni M**, Defrancesco I, Diamanti L, Marchioni E, Farina LM, Pichiecchio A. Bing-Neel Syndrome: Illustrative Cases and Comprehensive Review of the Literature. *Mediterr J Hematol Infect Dis* 2017; 9(1): e2017061.
  12. **Varettoni M**, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, Galli A, Porta MGD, Boveri E, Arcaini L, Candido C, Paulli M, Cazzola M. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. *Haematologica* 2017; 102: 2077-2085.
  13. Zaja F, Tabanelli V, Agostinelli C, Calleri A, Chiappella A, **Varettoni M**, Luigi Zinzani P, Volpetti S, Sabattini E, Fanin R, Pileri SA. CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? *Am J Hematol*. 2017; 92:E1-E2.
  14. Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, **Varettoni M**, Cartia CS, Cazzola M, Corso A. The possible role of burden of therapy on the risk of myeloma extramedullary spread. *Ann Hematol*. 2017;96:73-80.
  15. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, **Varettoni M**, Dimopoulos MA, Treon SP, Kastritis E. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. *Br J Haematol*. 2016; 175:77-86.
  16. Gotti M, Nicola M, Lucioni M, Fiaccadori V, Ferretti V, Sciarra R, Costanza M, Bono E, Molo S, Maffi A, Croci GA, **Varettoni M**, Frigeni M, Pascutto C, Arcaini L, Bonfichi M, Paulli M, Cazzola M. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma. *Hematol Oncol* 2017;35:296-30.
  17. Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, **Varettoni M**, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. *Br J Haematol* 2016;172:709-715.
  18. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, **Varettoni M**, Arcaini L, Munshi NM, Anderson KC, Treon SP. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. *Br J Haematol*. 2016 Mar; 172:735-744.
  19. Tiaci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, **Varettoni M**, Altman JK, Anastasia A,

- Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. *N Engl J Med*. 2015; 373:1733-1747.
20. **Varettoni M**, Marchioni E, Bonfichi M, Picchietto A, Arcaini L, Arbasino C, Gotti M, Da Vià M, Delmonte M, Sciarra R, Cazzola M. Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome. *Am J Hematol*. 2015;90:E152-153.
  21. Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, **Varettoni M**, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. *Leuk Lymphoma*. 2015;56:2637-2642.
  22. Arcaini L, Morello L, Tucci A, Rusconi C, Ladetto M, Rattotti S, Bonfichi M, Bottelli C, Gabutti C, Bernasconi P, **Varettoni M**, Gotti M, Troletti D, Guerrera ML, Fiaccadori V, Sciarra R, Ferretti VV, Alessandrino EP, Rossi G, Morra E. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. *Am J Hematol* 2015;90:230-234.
  23. Arcaini L, Rossi D, Lucioni M, Nicola M, Bruscaggini A, Fiaccadori V, Riboni R, Ramponi A, Ferretti VV, Cresta S, Casaluci GM, Bonfichi M, Gotti M, Merli M, Maffi A, Arra M, **Varettoni M**, Rattotti S, Morello L, Guerrera ML, Sciarra R, Gaidano G, Cazzola M, Paulli M. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. *Haematologica*. 2015;100:246-252.
  24. **Varettoni M**, Arcaini L, Rattotti S, Ferretti V, Cazzola M. Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. *Br J Haematol* 2015; 168:301-302.
  25. Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, **Varettoni M**, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. *Ann Oncol*. 2014;25:1404-1410.
  26. **Varettoni M**, Zibellini S, Arcaini L, Boveri E, Rattotti S, Pascutto C, Mangiacavalli S, Gotti M, Pochintesta L, Paulli M, Cazzola M. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. *Blood*;122: 2284-2285.
  27. Morra E, **Varettoni M**, Tedeschi A, Arcaini L, Ricci F, Pascutto C, Rattotti S, Vismara E, Paris L, Cazzola M. Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition. *Clin Lymphoma Myeloma Leuk*. 2013;13:700-703.
  28. Mangiacavalli S, Cocito F, Pochintesta L, Pascutto C, Ferretti V, **Varettoni M**, Zappasodi P, Pompa A, Landini B, Cazzola M, Corso A. Monoclonal gammopathy of undetermined significance: a new proposal of workup. *Eur J Haematol* 2013;91:356-360.
  29. Tedeschi A, Ricci F, Goldaniga MC, Benevolo G, **Varettoni M**, Motta M, Pioltelli P, Gini G, Barate' C, Luraschi A, Vismara E, Frustaci AM, Nichelatti M, Vitolo U, Baldini L, Morra E. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2013;13:231-234.
  30. Trojani A, Greco A, Tedeschi A, Lodola M, Di Camillo B, Ricci F, Turrini M, **Varettoni M**, Rattotti S, Morra E. Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. *Clin Lymphoma Myeloma Leuk*. 2013;13:208-210.
  31. **Varettoni M**, Zibellini S, Capello D, Arcaini L, Rossi D, Pascutto C, Rattotti S, Mangiacavalli S, Pochintesta L, Gotti M, Gaidano G, Cazzola M. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance

provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. *Leuk Lymphoma* 2013;54:2485-2489.

32. **Varettoni M**, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. *Blood*. 2013 Mar 28;121(13):2522-2528.
33. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, **Varettoni M**, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. *Blood*. 2013;121:2051-2058.
34. Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, **Varettoni M**, Guerrera ML, Lucioni M, Tenore A, Merli M, Rizzi S, Morello L, Cavalloni C, Da Vià MC, Paulli M, Cazzola M. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. *Blood*. 2012;119:188-191.
35. Tedeschi A, Benevolo G, **Varettoni M**, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioletti P, Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, Vitolo U, Morra E. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. *Cancer*. 2012;118:434-443.
36. **Varettoni M**, Tedeschi A, Arcaini L, Pascutto C, Vismara E, Orlandi E, Ricci F, Corso A, Greco A, Mangiacavalli S, Lazzarino M, Morra E. Risk of second cancers in Waldenström macroglobulinemia. *Ann Oncol*. 2012;23:411-415.
37. Ricci F, Tedeschi A, Vismara E, Greco A, Montillo M, Nichelatti M, **Varettoni M**, Lazzarino M, Morra E. The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenström's macroglobulinemia at diagnosis. *Clin Lymphoma Myeloma Leuk*. 2011 Feb;11(1):124-126.
38. Arcaini L, **Varettoni M**, Boveri E, Orlandi E, Rattotti S, Zibellini S, Merli M, Lucioni M, Rizzi S, Gotti M, Morello L, Pascutto C, Paulli M. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. *Clin Lymphoma Myeloma Leuk*. 2011;11:103-105.
39. Greco A, Tedeschi A, **Varettoni M**, Nichelatti M, Paris L, Ricci F, Vismara E, Morra E. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy. *Clin Lymphoma Myeloma Leuk*. 2011;11:77-79.
40. Merli M, Arcaini L, Boveri E, Rattotti S, Picone C, Passamonti F, Tenore A, Sozzani L, Lucioni M, **Varettoni M**, Rizzi S, Morello L, Ferretti V, Pascutto C, Paulli M, Lazzarino M. Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. *Eur J Haematol*. 2010;85:405-415.
41. **Varettoni M**, Corso A, Cocito F, Mangiacavalli S, Pascutto C, Zappasodi P, Pica G, Lazzarino M. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients. *Medicine (Baltimore)* 2010;89:211-216.
42. Zibellini S, Capello D, Forconi F, Marcatili P, Rossi D, Rattotti S, Franceschetti S, Sozzi E, Cencini E, Marasca R, Baldini L, Tucci A, Bertoni F, Passamonti F, Orlandi E, **Varettoni M**, Merli M, Rizzi S, Gattei V, Tramontano A, Paulli M, Gaidano G, Arcaini L. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. *Haematologica*. 2010;95:1792-1796.
43. Mangiacavalli S, Corso A, De Amici M, **Varettoni M**, Alfonsi E, Lozza A, Lazzarino M. Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. *Br J Haematol*. 2010;149:916-918.
44. Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, Pascutto C, **Varettoni M**, Bernasconi P, Grillo G, Carella AM, Montalbetti L, Lazzarino M, Morra E. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. *Leuk Lymphoma*. 2010;51:236-242.


45. Corso A, Mangiacavalli S, **Varettoni M**, Pascutto C, Zappasodi P, Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. *Leuk Res.* 2010;34:471-474.
46. **Varettoni M**, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. *Ann Oncol.* 2010;21(2):325-330.
47. Corso A, **Varettoni M**, Mangiacavalli S, Zappasodi P, Pica GM, Algarotti A, Pascutto C, Lazzarino M. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. *Eur J Haematol.* 2009;83:449-454.
48. Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro AM, **Varettoni M**, Gay F, Morra E, Lazzarino M. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. *Leuk Res.* 2009;33:e145-149.
49. Arcaini L, Zibellini S, Passamonti F, Rattotti S, Lucioni M, Invernizzi R, Merli M, Rizzi S, Boveri E, Rumi E, Astori C, Picone C, **Varettoni M**, Pascutto C, Paulli M, Lazzarino M. Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. *Blood Cells Mol Dis.* 2009;42:286-291.
50. Mangiacavalli S, Pica G, **Varettoni M**, Lazzarino M, Corso A. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients. *Eur J Haematol.* 2009;82:240-241.
51. Mangiacavalli S, **Varettoni M**, Zappasodi P, Pica G, Lazzarino M, Corso A. A striking response to bortezomib in a patient with pleural localization of multiple myeloma. *Leuk Res.* 2009;33:577-578.
52. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, **Varettoni M**, Zappasodi P, Moglia A, Lazzarino M, Costa A. Immune-mediated neuropathies in myeloma patients treated with bortezomib. *Clin Neurophysiol.* 2008;119:2507-2512.
53. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, Boggi S, Astori C, Bernasconi P, **Varettoni M**, Brusamolino E, Pascutto C, Lazzarino M. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. *Haematologica.* 2008;93:1645-1651.
54. **Varettoni M**, Corso A, Zappasodi P, Calliada F, Castagnola C, Mangiacavalli S, Lazzarino M. Infiltration of the spinal cord in a patient with multiple myeloma. *J Clin Oncol.* 2008;26:4207-4209.
55. Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, **Varettoni M**, Mangiacavalli S, Morra E, Lazzarino M, Corso A. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. *Transfusion.* 2008;48:857-860.
56. Corso A, **Varettoni M**. The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation? *Curr Stem Cell Res Ther.* 2007 Jan;2(1):1-11.
57. Corso A, Mangiacavalli S, Barbarano L, Montalbetti L, Mazzone A, Fava S, **Varettoni M**, Zappasodi P, Morra E, Lazzarino M. Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. *Leuk Res.* 2008 Jul;32(7):1085-1090.
58. **Varettoni M**, Mangiacavalli S, Zappasodi P, Pica GM, Lazzarino M, Corso A. Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas. *Leuk Res.* 2008;32:839-841.
59. Zappasodi P, Dore R, Castagnola C, Astori C, **Varettoni M**, Mangiacavalli S, Lazzarino M, Corso A. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. *J Clin Oncol.* 2007;25:3380-3381.
60. Mangiacavalli S, Zappasodi P, Castagnola C, Astori C, **Varettoni M**, Lazzarino M, Corso A. Severe intestinal vasculitis in a patient under treatment with bortezomib. *Ann Hematol.* 2007;86:923-924.
61. Corso A, **Varettoni M**, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. *Leukemia.* 2007;21(7):1545-1548.

62. **Varettoni M**, Vassallo C, Borroni G, Mangiacavalli S, Zappasodi P, Rosso R, Lazzarino M, Corso A. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. *Ann Hematol*. 2007;86:301-302.
63. Zappasodi P, Mangiacavalli S, Terulla V, Airò F, Klersy C, **Varettoni M**, Corso A. Thrombomodulin levels are not modified during thalidomide treatment. *Eur J Haematol*. 2006;77:453-454.
64. Zappasodi P, Corso A, Klersy C, Pica G, Mangiacavalli S, **Varettoni M**, Rusconi C, Pascutto C, Lazzarino M. Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience. *Eur J Cancer*. 2006;42(3):396-402.
65. Corso A, Mangiacavalli S, Nosari A, Castagnola C, Zappasodi P, Cafo AM, Astori C, Bonfichi M, **Varettoni M**, Rusconi C, Troletti D, Pascutto C, Morra E, Lazzarino M; HOST Group. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. *Bone Marrow Transplant*. 2005;36:951-954.
66. Lazzarino M, Arcaini L, Orlandi E, Iacona I, Bernasconi P, Calatroni S, **Varettoni M**, Isa L, Brusamolino E, Bonfichi M, Passamonti F, Burcheri S, Pascutto C, Regazzi M. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. *Oncology*. 2005;68:146-153.
67. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, Rusconi C, **Varettoni M**, Lazzarino M. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. *Cancer*. 2005;104:118-125.
68. Morra E, Cesana C, Klersy C, Barbarano L, Miqueleiz S, **Varettoni M**, Lucchesini C, Ricci F, Lazzarino M. Prognostic factors for transformation in asymptomatic immunoglobulin m monoclonal gammopathies. *Clin Lymphoma*. 2005;5:265-269.
69. Cesana C, Barbarano L, Miqueleiz S, Lucchesini C, Ricci F, **Varettoni M**, Filippini D, Lazzarino M, Morra E. Clinical characteristics and outcome of immunoglobulin M-related disorders. *Clin Lymphoma*. 2005;5:261-264.
70. Corso A, **Varettoni M**, Mangiacavalli S, Zappasodi P, Klersy C, Rusconi C, Colucci E, Lorenzi A, Troletti D, Consensi E, Lazzarino M. Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection. *Leuk Res*. 2005;29:159-163.
71. Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, **Varettoni M**, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. *Bone Marrow Transplant*. 2004;34:1039-1045.
72. Vassallo C, Brazzelli V, Alessandrino PE, **Varettoni M**, Ardigò M, Lazzarino M, Borroni G. Normal-looking skin in oncohaematological patients after allogeneic bone marrow transplantation is not normal. *Br J Dermatol*. 2004;151:579-586.
73. Morra E, Cesana C, Klersy C, Barbarano L, **Varettoni M**, Cavanna L, Canesi B, Tresoldi E, Miqueleiz S, Bernuzzi P, Nosari AM, Lazzarino M. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. *Leukemia*. 2004;18:1512-1517.
74. Corso A, Dovio A, Rusconi C, Sartori ML, Klersy C, **Varettoni M**, Mangiacavalli S, Zappasodi P, Ventura M, Angeli A, Lazzarino M. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. *Leukemia*. 2004;18:1555-1557.
75. Corso A, Lorenzi A, Terulla V, Airò F, **Varettoni M**, Mangiacavalli S, Zappasodi P, Rusconi C, Lazzarino M. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. *Ann Hematol*. 2004;83:588-591.
76. Orlandi E, **Varettoni M**, Bergamaschi G, Lazzarino M. First episode of acute hemolysis due to G6PD deficiency in a middle-aged woman and transmission of the enzymatic defect through bone marrow transplant. *Haematologica*. 2004;89:ECR04.
77. Morra E, Cesana C, Klersy C, **Varettoni M**, Cavanna L, Canesi B, Tresoldi E, Barbarano L, Lazzarino M; Hematology/Oncology Studies and Trials (HOST) Group, Italy. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy. *Semin Oncol*. 2003;30:172-177.

78. Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Bonfichi M, Pagnucco G, Malcovati L, **Varettoni M**, Lazzarino M, Bernasconi C. Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. *Ann Hematol.* 2001;80:521-524.
79. Brazzelli V, Ardigò M, Chiesa MG, Vassallo C, **Varettoni M**, Borroni RG, Alessandrino EP, Borroni G. Flexural erythematous eruption following autologous peripheral blood stem cell transplantation: a study of four cases. *Br J Dermatol.* 2001;145:490-5.
80. Alessandrino EP, **Varettoni M**, Colombo AA, Caldera D, Bernasconi P, Malcovati L. High incidence of symptomatic cytomegalovirus infection in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. *Blood.* 2000;95:4016-4018.
81. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, Malcovati L, Nascimbene C, **Varettoni M**, Volpini E, Klersy C, Bernasconi C. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. *Bone Marrow Transplant.* 2000;25:309-13.
82. Alessandrino P, Bernasconi P, Caldera D, Colombo A, Bonfichi M, Malcovati L, Klersy C, Martinelli G, Maiocchi M, Pagnucco G, **Varettoni M**, Perotti C, Bernasconi C. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. *Bone Marrow Transplant.* 1999;23:533-537.

Pavia, 7 aprile 2020

Dott.ssa Marzia Varettoni



---